new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
Published 2 years ago • 926 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
1:59
phase iii trial of imetelstat versus best available therapy in refractory mf
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
1:44
an update on imetelstat in r/r myelofibrosis
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
7:06
next-level iol outcomes for presbyopia with the well fusion system
-
1:03:27
[online seminar] new holladay report for best results in iol calculations & refractive surgery
-
4:16
over priming or under filling
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:53
the latest clinical updates on navtemadlin for the treatment of mpns
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
25:35
investor webinar: azer-cel trial update, september 2024
-
2:44
trial in progress: anti-slamf7 elotuzumab in jak2-mutated myelofibrosis
-
1:30
mdm2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
-
1:22
exciting upcoming mpns trials: v617f-targeted jak2 inhibitors and anti-calreticulin antibodies
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
0:34
imi is revolutionising clinical trials
-
50:02
evolut pro valve-in-valve - live case 2
-
1:35
trial in progress: pelcitoclax monotherapy, and in combination with jak2 inhibition in mf
-
5:01
clearify™ visualization system - inservice video
-
3:22
jak2 inhibition in the treatment of myelofibrosis